The Shoulder Arthroplasty Product Management and Engineering teams performed a validation lab for the new Univers Revers™ Modular Glenoid System (MGS) last month in an effort to get this latest innovative product to market quickly. Professor Dr. med. Peter Habermeyer of Munich, Germany, (center left) evaluates instrumentation for the Univers Revers™ Modular Glenoid System during a validation lab on April 19, at Arthrex global headquarters. The Shoulder Arthroplasty Team had nine surgeons validate the new product over the course of 1 day in order to get FDA cleared through the 510(k) premarket notification process. The FDA issued the 510(k) clearance letter for the Modular Glenoid System on April 20.
Shoulder Arthroplasty Team Secures Successful FDA Approval for New Product
2018-05-22T15:47:26+02:0022.05.2018|Allgemein, Presse, Publikationen|